PHE885 is an autologous T cell genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process that is being tested in patients with multiple myeloma.
| SparkCures ID | 376 |
|---|---|
| Developed By | Novartis |
| Generic Name | PHE885 |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
There are no resources, links or videos to display for this treatment.